Table 2.

Methodologies used to overproduce drugs using engineered metabolic networks approach.

Strains	Drugs	Approach	Methodologies
S. rimosus M4018	Oxytetracycline	Engineered metabolic networks	Deletion of zwf1 and zwf2 genes improve the production of oxytetracycline
S. roseosporus	Daptomycin	Engineered metabolic networks	Over-expression of zwf2 gene improve the production of daptomycin
S. lividans	Actinorhodin and undecylprodigiosin	Engineered metabolic networks	Deletion of zwf1 or zwf2 improved actinorhodin and undecylprodigiosin production
S. coelicolor A3 (2)	Actinorhodin and undecylprodigiosin	Engineered metabolic networks	Deletion of pfkA2 (phosphofructokinase) gene improve the production of actinorhodin and undecylprodigiosin
S. noursei NRRL 5126	ε-Poly-l-Lysine	Engineered metabolic networks	Supplementation of citric acid and L-Asp increases poly-ε-lysine production
S. tsukubaensis	FK506 (tacrolimus)	Engineered metabolic networks	Enhancing the biosyntheses of methoxymalonyl-ACP and allylmalonyl-CoA together with optimized glucose concentrations enhances the FK506 production
S. peucetius ATCC 27952	Doxorubicin	Engineered metabolic networks	Over-expression of potential biosynthetic sugar genes and glycosyltransferase enhanced doxorubicin production